Mouse Anti-SNCA Recombinant Antibody (clone 4B12) (CAT#: VS-0224-FY1)
This product is a recombinant antibody that recognizes α-Synuclein. This antibody reacts with human a-synuclein. It does not react with mouse or rat a-synuclein. The epitope lies within AA 103-108 of a-synuclein.
Specific Inquiry
Custom Production
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
We require custom production
Normal Tissue
RNA Expression
Figure 1 High expression in cerebral cortex
(Neuropil Staining: High Intensity: Strong Quantity:>75% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/5459/164874_B_9_5.jpg
(Neuropil Staining: High Intensity: Strong Quantity:>75% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/5459/164874_B_9_5.jpg
Figure 2 Colon
(Peripheral nerve/ganglion Staining: High Intensity: Strong Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/10877/164900_A_7_3.jpg
(Peripheral nerve/ganglion Staining: High Intensity: Strong Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/10877/164900_A_7_3.jpg
Figure 3 Kidney
(Cells in glomeruli Staining: High Intensity: Strong Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/5459/164893_A_7_5.jpg
(Cells in glomeruli Staining: High Intensity: Strong Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/5459/164893_A_7_5.jpg
Figure 4 Testis
(Leydig cells Staining: Medium Intensity: Moderate Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/5459/164893_A_6_6.jpg
(Leydig cells Staining: Medium Intensity: Moderate Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/5459/164893_A_6_6.jpg
Figure 5 Bone marrow
(Hematopoietic cells Staining: High Intensity: Strong Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/5459/164874_B_4_4.jpg
(Hematopoietic cells Staining: High Intensity: Strong Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/5459/164874_B_4_4.jpg
Figure 6 RNA cell line category: Cell line enhanced (HEL, HUVEC TERT2, RT4, SK-MEL-30, TIME)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas v21.proteinatlas.org/ENSG00000145335-SNCA
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas v21.proteinatlas.org/ENSG00000145335-SNCA
Specifications
- Immunogen
- Purified E. coli produced human α-synuclein.
- Host Species
- Mouse
- Type
- Mouse IgG1, κ
- Specificity
- The antibody binds to residues 103-108 of human a-synuclein.
- Species Reactivity
- Human
- Clone
- 4B12
- Applications
- Immunohistochemistry, ELISA, Western Blot, Immunoprecipitation
- Conjugate
- Unconjugated, Biotin and HRP formats are available.
- Related Disease
- Alzheimer's disease
Product Property
- Purity
- >95%
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS
- Preservative
- Without preservatives or carrier proteins
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Applications
- Application Notes
- Immunohistochemistry: 1-2.5 µg/mL
Western blot: 1-10 µg/mL
Target
- Alternative Names
- Synuclein Alpha; Synuclein, Alpha (Non A4 Component Of Amyloid Precursor); Alpha-Synuclein; PARK1; NACP; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Non A4 Component Of Amyloid Precursor; Non-A4 Component Of Amyloid Precursor
- Gene ID
- 6622
- UniProt ID
- P37840
Recommended Products
Isotype Control
Secondary Antibody
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "SNCA"
Select a product category from the dropdown menu below to view related products.
Please select product type
Intrabodies
Single Domain Antibodies
Chimeric Antibodies
Mouse Antibodies
Blocking Antibodies
Rabbit Monoclonal Antibodies
Neuroscience Antibodies
ScFv Antibodies
Fab Antibodies
IgG Antibodies
Antibody Magnetic Beads
ScFv-Fc Chimeras
IHC Kits & Antibodies
| CAT | Product Name | Application | Type |
|---|---|---|---|
| IAB-B031(A) | Recombinant Anti-human SNCA Intrabody [(D-Arg)9] | FC, IF, FuncS | scFv-(D-Arg)9 |
| IAB-B031(G) | Recombinant Anti-human SNCA Intrabody [+36 GFP] | CO-IP, FuncS | scFv-(+36GFP) |
| IAB-B031(T) | Recombinant Anti-human SNCA Intrabody [Tat] | ELISA, IF, Neut, FuncS | scFv-Tat |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-0224-FY1. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: WB, ELISA, FC, IP, FuncS, IF, Neut
Application: ELISA, SPR, Inhib, FuncS
Application: FC, IB, Block, Inhib, FuncS, ELISA, FACS, IP, IF
-2.png)
Application: WB, ELISA, FC, IHC, IP
Application: ELISA
-3.jpg)
Application: Neut
Application: ELISA, WB, FC, IHC, IP
Application: WB, ELISA, IHC, IP, SPR, FuncS
Application: FC, IHC, Cyt, FuncS
-4.jpg)
Application: FC, FuncS, IA, IF, IP, IHC
Application: ELISA, Vaccine, FuncS
For Research Use Only. Not For Clinical Use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
